StreetInsider.com News Articles

Form 8-K DNA X, Inc. For: Aug 21

Thu, 27 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260827/26984804.html

Form 8-K DNA X, Inc. For: Aug 21

Thu, 27 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260827/26984804.html

Form 10-Q DNA X, Inc. For: Jun 30

Wed, 19 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260819/26950554.html

Form 10-Q DNA X, Inc. For: Jun 30

Wed, 19 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260819/26950554.html

DNA X, Inc. Reports Second Quarter 2026 Financial Results

Wed, 19 Aug 2026 16:15:00 -0400

-Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end

-Converted $3.1 million outstanding note to preferred stock, further optimizing the balance sheet

SAN DIEGO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- DNA X, Inc. (Nasdaq: SONM) (“DNA X” or the “Company”), a developer of intelligent digital-asset technologies, today announced financial results for the second quarter ended June 30, 2026.

“The second quarter marked an important milestone as we secured the capital and resources necessary to advance our strategic priorities

DNA X, Inc. Reports Second Quarter 2026 Financial Results

Wed, 19 Aug 2026 16:15:00 -0400

-Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end

-Converted $3.1 million outstanding note to preferred stock, further optimizing the balance sheet

“The second quarter marked an important milestone as we secured the capital and resources necessary to advance our strategic priorities

DNA X, Inc. Reports Second Quarter 2026 Financial Results

Wed, 19 Aug 2026 16:15:00 -0400

-Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end

-Converted $3.1 million outstanding note to preferred stock, further optimizing the balance sheet

“The second quarter marked an important milestone as we secured the capital and resources necessary to advance our strategic priorities

DNA X, Inc. Reports Second Quarter 2026 Financial Results

Wed, 19 Aug 2026 16:15:00 -0400

-Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end

-Converted $3.1 million outstanding note to preferred stock, further optimizing the balance sheet

“The second quarter marked an important milestone as we secured the capital and resources necessary to advance our strategic priorities

Form NT 10-Q DNA X, Inc. For: Jun 30

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930297.html

Form NT 10-Q DNA X, Inc. For: Jun 30

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930297.html

Form 8-K/A DNA X, Inc. For: Jun 29

Thu, 13 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26920558.html

Form 8-K/A DNA X, Inc. For: Jun 29

Thu, 13 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26920558.html

Form SCHEDULE 13G/A DNA X, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26919826.html

Form SCHEDULE 13G/A DNA X, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26919826.html

Form 8-K/A DNA X, Inc. For: Jun 29

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753238.html

Form 8-K/A DNA X, Inc. For: Jun 29

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753238.html

DNA X raises $8.1M via preferred stock sale to related-party investor

Thu, 02 Jul 2026 08:58:28 -0400

DNA X, Inc. (NASDAQ: SONM), formerly known as Sonim Technologies, entered into a securities purchase agreement on June 29, 2026, to sell 1,346,531 shares of Series B Convertible Preferred Stock to DNA Holdings Venture, Inc. at $6.00 per share, for an aggregate offering price of $8.1 million.

DNA Holdings is both a holder of more than 5% of the company's outstanding capital stock and an entity associated with Scott Walker, a member of the company's board of directors. The transaction consists of $5.0 million in cash and the cancellation of $3.1 million in outstanding balance under a convertible promissory note issued

DNA X raises $8.1M via preferred stock sale to related-party investor

Thu, 02 Jul 2026 08:58:28 -0400

Form 8-K DNA X, Inc. For: Jun 29

Thu, 02 Jul 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260702/26724567.html

Form 8-K DNA X, Inc. For: Jun 29

Thu, 02 Jul 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260702/26724567.html

Form EFFECT DNA X, Inc.

Fri, 12 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260612/26637892.html

Form EFFECT DNA X, Inc.

Fri, 12 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260612/26637892.html

Form POS AM DNA X, Inc.

Mon, 08 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260608/26618109.html

Form POS AM DNA X, Inc.

Mon, 08 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260608/26618109.html

Form 8-K DNA X, Inc. For: May 29

Thu, 04 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260604/26606478.html